Search by Abstract Number Results

Abstract Number: 1648 • ACR Convergence 2024
In Vitro Expansion of ACPA-positive B Cells from Rheumatoid Arthritis Patients and Effect of Small Molecule NF-κB Inhibitors on Differentiation and Survival of (Autoreactive) Memory B Cells into Plasma Cells
Giulia Frazzei¹, Ana Merino Vico², Jan Piet van Hamburg², Ronald Van Vollenhoven³ and Sander Tas⁴, ¹Amsterdam University Medical Center, location AMC, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands, ³Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁴Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) play a role in rheumatoid arthritis (RA) pathogenesis and are associated with disease severity. Detailed analysis of ACPApos B cells…
Abstract Number: 1648 • ACR Convergence 2023
EULAR Recommendations for the Use of Imaging in Large Vessel Vasculitis in Clinical Practice: 2023 Update
Christian Dejaco¹, Sofia Ramiro², Milena Bond³, Philipp Bosch⁴, Cristina Ponte⁵, Sarah Mackie⁶, Thorsten Bley⁷, Daniel Blockmans⁸, Sara Brolin⁹, Ertugrul Cagri Bolek¹⁰, Rebecca Cassie¹¹, Maria C Cid¹², Juan Molina-Collada¹³, Bhaskar Dasgupta¹⁴, Berit Dalsgaard Nielsen¹⁵, Eugenio De Miguel¹⁶, Haner Direskeneli¹⁷, Christina Duftner¹⁸, Alojzija Hocevar¹⁹, Anna Molto²⁰, Valentin Sebastian Schäfer²¹, Luca Seitz²², Riemer H.J.A. Slart²³ and Wolfgang Schmidt²⁴, ¹Azienda Sanitaria Alto Adige, Brunico, Italy, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Azienda sanitaria dell'Alto Adige, Merano, Italy, ⁴Medical University of Graz, Graz, Austria, ⁵Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Institute of Diagnostic and Interventional Radiology, University Hospital Würzburg, Würzburg, Germany, ⁸Department of General Internal Medicine, University Hospitals Leuven, Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium, ⁹Karolinska University Hospital, and Karolinska Institutet, Stockholm, Sweden, ¹⁰1-Hacettepe University Vasculitis Research Centre, Ankara, Turkey/ 2-Vasculitis Translational Research Program, NIAMS, NIH, US, Ankara, Turkey, ¹¹n/a, Leicester, United Kingdom, ¹²Hospital Clinic Barcelona, Barcelona, Spain, ¹³Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹⁴Mid & South Essex University Hospitals NHS Foundation Trust; Southend University Hospital, Westcliff-on-sea, United Kingdom, ¹⁵Department of Internal Medicine, Horsens, Denmark, ¹⁶Hospital Universitario La Paz, Madrid, Spain, ¹⁷Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey, ¹⁸Medical University Innsbruck, Innsbruck, Austria, ¹⁹Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia, ²⁰HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ²¹Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, ²²Rheumatology and Immunology, Inselspital University Hospital Bern, Bern, Switzerland, ²³University of Twente, Enschede, Netherlands, ²⁴Rheumatology, Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany
Background/Purpose: Imaging recommendations for primary large vessel vasculitis (LVV) were developed in 2018. Several new studies have emerged since then, and an update of the…
Abstract Number: 1648 • ACR Convergence 2022
Risk of Vascular Events Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
Eiichi Tanaka¹, Ryoko Sakai², Eisuke Inoue³ and Masayoshi Harigai¹, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Meiji Pharmaceutical University, Tokyo, Japan, ³Research Administration Center, Showa University, Shinagawa-ku, Japan
Background/Purpose: Janus kinase inhibitors (JAKIs) have shown positive therapeutic impacts on treatments for rheumatoid arthritis (RA), whereas, concerns have been raised about the risk of…
Abstract Number: 1648 • ACR Convergence 2021
Increasing Rates of Positivity of Autoantibodies Indicates a Shorter Time-to-Diagnosis of Future Rheumatoid Arthritis
Dylan Bergstedt¹, Ryan Peterson², Marie Feser¹, LauraKay Moss¹, Geoffrey Thiele³, Ted Mikuls³, Jess Edison⁴, V. Michael Holers¹ and Kevin Deane⁵, ¹University of Colorado Denver, Aurora, CO, ²Colorado School of Public Health, Aurora, CO, ³University of Nebraska Medical Center, Omaha, NE, ⁴Walter Reed National Military Medical Center, Bethesda, MD, ⁵University of Colorado Denver, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period that can be defined by elevations in autoantibodies to citrullinated protein antigens (ACPA) and rheumatoid factor (RF)…
Abstract Number: 1648 • ACR Convergence 2020
Comparison of Methotrexate and Glucosamine in Primary Knee Osteoarthritis with Inflammation
Biswadip Ghosh¹, Subhankar Haldar² and Meghna Saha², ¹IPGME&R, Kolkata, Kolkata, West Bengal, India, ²IPGME&R, Kolkata, KOLKATA, India
Background/Purpose: Many patients suffering from knee OA show swelling, warmth along with pain which are features of inflammation. There are no accepted pharmacological therapy for osteoarthritis…
Abstract Number: 1648 • 2019 ACR/ARP Annual Meeting
Systemic Sclerosis Auto-antibody Profiles Predict Interstitial Lung Disease Onset but Not Progression
Boyang Zheng¹, Mianbo Wang ², Marvin Fritzler ³, May Choi ³, Murray Baron ⁴ and Marie Hudson ⁵, ¹Jewish General Hospital, McGill University, Montreal, QC, Canada, ²Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Jewish General Hospital, McGill University, Montreal, Canada, ⁵Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: Interstitial lung disease (ILD) is frequent manifestation and a leading cause of mortality in systemic sclerosis (SSc). Some SSc-related autoantibodies (aAbs), especially anti-topoisomerase I…
Abstract Number: 1648 • 2018 ACR/ARHP Annual Meeting
Smoking Status in Patients with Psoriasis and Psoriatic Arthritis: An Irish Perspective
Conor Magee¹, Oliver FitzGerald², Flora Farkas¹, Natsumi Ikumi¹, Phil Gallagher³, Agnes Szentpetery⁴ and Brian Kirby⁵, ¹Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ²Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, ³St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁴Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ⁵Dermatology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: The BIOmarkers of COMorbidities (BIOCOM) in psoriasis study is a longitudinal study which aims to identify clinical, genetic or protein biomarker features associated with…
Abstract Number: 1648 • 2017 ACR/ARHP Annual Meeting
Assessment of Outcome in Lupus Nephritis Patients: A Retrospective Analysis of a Single Center Cohort over 20 Years
Lihi Shemesh Eisen¹, Talia Weinstein², Irena Litinsky³, David Levartovsky¹, Ilana Kaufman¹, Marina Anouk⁴, Valerie Aloush⁴, Jonathan Wollman⁵, Jacob N. Ablin⁶, Uri Arad¹, Mark Berman¹, Victoria Furer¹, Ari Polachek⁷, Ofir Elalouf⁸, Sara Borok Lev-Ran¹, Reut Zemach⁹, Tali Eviatar¹, Michael Zisapel¹, Hagit Sarvagyl-Maman¹⁰, Dan Caspi¹¹, Ori Elkayam⁴ and Daphna Paran⁴, ¹Rheumatology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ²Nephrology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ³Rheumatology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁴Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁵Rheumatology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine ,Tel-Aviv University, Tel-Aviv, Israel, ⁶Internal Medicine H, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁷Rheumatology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv Univrsity, Tel Aviv, Israel, ⁸Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁹Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ¹⁰Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-aviv, Israel, ¹¹Rheumatology, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel
Background/Purpose: Lupus Nephritis (LN) is a severe SLE manifestation, leading to a six-fold increased risk of death. This study aims to assess the outcome of…
Abstract Number: 1648 • 2016 ACR/ARHP Annual Meeting
Long-Term Clinical, Radiographic and Patient-Reported Outcomes Based on RAPID3 Responses with Tofacitinib at 6 Months
Vibeke Strand¹, Martin J Bergman², Eun Bong Lee³, Yusuf Yazici⁴, Bethanie Wilkinson⁵, Liza Takiya⁶, Gene Wallenstein⁵, Chuanbo Zang⁷ and Eustratios Bananis⁷, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Taylor Hospital, Ridley Park, PA, ³Seoul National University, Seoul, Korea, Republic of, ⁴New York University, Hospital of Joint Diseases, New York, NY, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. RAPID3 (Routine Assessment of Patient [Pt] Index Data 3) is a pooled…
Abstract Number: 1648 • 2015 ACR/ARHP Annual Meeting
The Balance of Foxp3/Ror-Gammat Expression Is Altered By Tocilizumab and By Abatacept in Patients with Rheumatoid Arthritis
Yoshifumi Tada¹, Syuichi Koarada², Nobuyuki Ono², Akihito Maruyama², Satoko Tashiro², Yukiko Tokuda², Yukihide Ono², Yoshinobu Nakao² and Akihide Ohta³, ¹Department of Internal Medicine, Division of Rheumatology, Saga University, Saga, Japan, ²Rheumatology, Saga University, Saga, Japan, ³Department of Adult and Gerontological Nursing, Saga University School of Medicine, Saga, Japan
Background/Purpose: It has been shown that the balance between Th17 cells and regulatory T (Treg) cells plays an important role for the development of autoimmune…
Abstract Number: 1648 • 2014 ACR/ARHP Annual Meeting
Urinary T Cells and Macrophages Strongly Reflect the Disease Activity, Kidney Function, and the Histopathologic Classification in Patients with Lupus Nephritis
Yoko Wada¹, Minoru Sakatsume², Masaaki Nakano³ and Ichiei Narita¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ³School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan
Background/Purpose: Lupus nephritis (LN) is one of the common manifestations of systemic lupus erythematosus (SLE), and the occurrence of LN is considered to be a…
Abstract Number: 1648 • 2013 ACR/ARHP Annual Meeting
PD-1⁺CD45RB^lo122^lo Autoantibody-Inducing CD4 T Cells (aiCD4 T cells) As a Key In The Pathogenesis Of Systemic Lupus Erythematosus (SLE)
Yumi Miyazaki¹, Ken Tsumiyama² and Shunichi Shiozawa¹, ¹Department of Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ²Department of Rheumatology, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: We found that systemic lupus erythematosus (SLE) was induced experimentally by repeatedly immunizing the mice normally not prone to autoimmune diseases by any exogenous…
Abstract Number: 1648 • 2012 ACR/ARHP Annual Meeting
Lupus Anticoagulant At First Pregnancy Visit Is Predictive of Pregnancy Loss
Michelle Petri¹, Anil Mankee², Ehtisham Akhter², Hong Fang¹ and Laurence S. Magder³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Multiple factors, including proteinuria, antiphospholipid syndrome, thrombocytopenia and hypertension, are predictive of pregnancy loss in SLE. In the PROMISSE study of mediators of pregnancy…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].